Robert Freedman is co-chair of the Securities & Corporate Finance group and provides corporate and securities law services to late stage and public technology and life sciences companies. He leads initial public offerings and follow-on offerings of equity and debt, and focuses on advising boards and management on corporate and securities law compliance and disclosure matters. Rob has represented issuers and underwriters in securities offerings by public companies for over 20 years. Rob also concentrates on mergers and acquisitions and private financings for public companies.
Representative Clients:
- Aeglea BioTherapeutics
- AnaptysBio
- Audentes Therapeutics
- BioPharmX
- Corium International
- Concur Technologies
- Data Domain
- DexCom
- Handspring
- Keynetics
- Loxo Oncology
- Macromedia
|
- Marvell Technology Group
- Merrill Lynch & Co.
- Opsware
- OrbiMed Advisors
- ProNAi Therapeutics
- ServiceNow
- Shutterfly
- Silver Spring Networks
- Thomas Weisel Partners
- ZymoGenetics
|
Representative IPO Clients:
- Aeglea BioTherapeutics
- Castlight Health
- Corium International
- Cowen and Company
- Dermira
- DexCom
- J.P. Morgan Securities
|
- Loxo Oncology
- Planet Payment
- Piper Jaffray & Co.
- ProNAi Therapeutics
- ServiceNow
- Shutterfly
- Silver Springs Networks
|
Representative M&A and Tender Offer Experience:
- DexCom acquisition of SweetSpot Diabetes Care
- Zappos.com,’s acquisition by Amazon.com,
- Alpha Innotech’s acquisition by Cell Biosciences
- Data Domain’s acquisition by EMC
- Cisco Systems’s acquisition of WebEx Communications
- Macromedia’s merger with Adobe
Rob is admitted to practice only in California, Idaho and Washington. He received his A.B. degree in biochemistry and history in 1987 from Bowdoin College where he graduated summa cum laude and Phi Beta Kappa. He received his J.D. degree, with distinction, in 1993 from Stanford University.
In 2015, Robert was recommended by The Legal 500 for his individual practice and role as co-chair of Fenwick’s corporate and securities practice, which was recognized as a team of “highly knowledgeable and flexible technology sector specialists.”
Rob is the co-chair for the Practising Law Institute’s “How to Prepare an Initial Public Offering” program.
Prior to law school, Rob was a banker for Manufacturers Hanover Trust in New York.
Sophia Hudson is a capital markets partner in the New York office of Kirkland & Ellis LLP. Sophia advises issuers and underwriters on capital markets transactions, including initial public offerings and follow-on equity offerings, public and private high-yield, investment-grade and convertible debt offerings and private placements of equity and convertible securities for early stage companies. She also counsels her corporate clients, including management teams and boards of directors, on governance, corporate and securities law matters.
Her experience ranges across a variety of industries, including biotech, consumer, financials, industrials, mining, retail, specialty pharmaceuticals and technology. She has represented all the major U.S. investment banks.
